» Articles » PMID: 38219913

Protein Subunit Vaccines: Promising Frontiers Against COVID-19

Overview
Specialty Pharmacology
Date 2024 Jan 14
PMID 38219913
Authors
Affiliations
Soon will be listed here.
Abstract

The emergence of COVID-19 has posed an unprecedented global health crisis, challenging the healthcare systems worldwide. Amidst the rapid development of several vaccine formulations, protein subunit vaccines have emerged as a promising approach. This article provides an in-depth evaluation of the role of protein subunit vaccines in the management of COVID-19. Leveraging viral protein fragments, particularly the spike protein from SARS-CoV-2, these vaccines elicit a targeted immune response without the risk of inducing disease. Notably, the robust safety profile of protein subunit vaccines makes them a compelling candidate in the management of COVID-19. Various innovative approaches, including reverse vaccinology, virus like particles, and recombinant modifications are incorporated to develop protein subunit vaccines. In addition, the utilization of advanced manufacturing techniques facilitates large-scale production, ensuring widespread distribution. Despite these advancements, challenges persist, such as the requirement for cold-chain storage and the necessity for booster doses. This article evaluates the formulation and applications of protein subunit vaccines, providing a comprehensive overview of their clinical development and approvals in the context of COVID-19. By addressing the current status and challenges, this review aims to contribute to the ongoing discourse on optimizing protein subunit vaccines for effective pandemic control.

Citing Articles

Development of a Recombinant Omicron BA.1 Subunit Vaccine Candidate in Pichia pastoris.

Kalyoncu S, Sayili D, Kuyucu A, Soyturk H, Gullu S, Ersayan B Microb Biotechnol. 2025; 18(1):e70077.

PMID: 39815667 PMC: 11735458. DOI: 10.1111/1751-7915.70077.


A Subunit Vaccine Harboring the Fusion Capsid Proteins of Porcine Circovirus Types 2, 3, and 4 Induces Protective Immune Responses in a Mouse Model.

Wang Q, Zhang R, Wang Y, Wang Y, Liang L, Ma H Viruses. 2025; 16(12.

PMID: 39772270 PMC: 11728783. DOI: 10.3390/v16121964.


Single dose of recombinant baculovirus vaccine expressing sigma B and sigma C genes provides good protection against novel duck reovirus challenge in ducks.

Wang Y, Xu S, Chen X, Dou Y, Yang X, Hu Z Poult Sci. 2024; 104(1):104565.

PMID: 39631275 PMC: 11652866. DOI: 10.1016/j.psj.2024.104565.


Prokaryote- and Eukaryote-Based Expression Systems: Advances in Post-Pandemic Viral Antigen Production for Vaccines.

Khudainazarova N, Granovskiy D, Kondakova O, Ryabchevskaya E, Kovalenko A, Evtushenko E Int J Mol Sci. 2024; 25(22).

PMID: 39596049 PMC: 11594041. DOI: 10.3390/ijms252211979.


Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection.

Yang K, Zeng Y, Wu X, Li J, Guo J Front Immunol. 2024; 15:1392898.

PMID: 39351240 PMC: 11440195. DOI: 10.3389/fimmu.2024.1392898.